Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated...
Company to report second quarter 2026 financial results on August 6 SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company...
SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary...
SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant...
No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Vaxart,...
Company to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees Stockholder Group Withdraws Director Nominations SOUTH...
Details Strategic Actions Taken by the Board to Advance the Company’s Pipeline and Drive Value Creation Vaxart’s Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase...
Latest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort Funding to Advance Data Analysis from More Than 5,000 Trial Participants Ahead of...
Urges Stockholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN...
SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary...